An experimental model for interpreting percutaneous penetration of oligonucleotides that incorporates the role of keratinocytes

被引:11
作者
Brand, RM
Haase, K
Hannah, TL
Iversen, PL
机构
[1] Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA
[2] Univ Nebraska, Med Ctr, Dept Internal Med, Sect Diabet Endocrinol & Metab, Omaha, NE USA
[3] Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE USA
[4] AVI Biopharm, Corvallis, OR USA
关键词
cellular uptake; iontophoresis; skin; transdermal delivery;
D O I
10.1046/j.1523-1747.1998.00453.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Oligonucleotides have been extensively studied for their potential as therapeutic agents. Phosphorothioate oligonucleotides have been demonstrated to be particularly useful due to their stability against nucleases, their ability to be internalized by many cell types, and the ease with which they hybridize with target mRNA. These compounds have previously been delivered across the skin with the aid of iontophoresis, During transdermal delivery, the first viable cells exposed to the oligonucleotides are the keratinocytes, The purpose of this study was to determine the relationship between internalization of these compounds by keratinocytes and their transport across the skin. The in vitro uptake of 15 different fluorescently labeled phosphorothioate oligonucleotides into human keratinocytes was quantitatively measured with a fluorometer, Photomicrographs of keratinocytes indicate diffuse cytoplasmic and nuclear localization. The ability of these molecules to enter cells was linearly related to size. Cellular uptake data were inversely correlated with previously reported steady-state transport levels of oligonucleotides that had been transdermally delivered by iontophoresis across hairless mouse skin. Oligonucleotides that readily entered keratinocytes had a decreased ability to penetrate skin under iontophoretic conditions. The results indicate that oligonucleotide sequences may be designed for treating skin diseases (high uptake, low transport) or systemic disorders (low uptake, high transport).
引用
收藏
页码:1166 / 1171
页数:6
相关论文
共 19 条
[1]   Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome [J].
Bishop, MR ;
Jackson, JD ;
Tarantolo, SR ;
OKaneMurphy, B ;
Iversen, PL ;
Bayever, E ;
Joshi, SM ;
Sharp, JG ;
Pierson, JL ;
Warkentin, PI ;
Armitage, JO ;
Kessinger, A .
JOURNAL OF HEMATOTHERAPY, 1997, 6 (05) :441-446
[2]   Effects of size and sequence on the iontophoretic delivery of oligonucleotides [J].
Brand, RM ;
Wahl, A ;
Iversen, PL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (01) :49-52
[3]   Iontophoretic delivery of a telomeric oligonucleotide [J].
Brand, RM ;
Iversen, PL .
PHARMACEUTICAL RESEARCH, 1996, 13 (06) :851-854
[4]   OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS [J].
COHEN, JS .
PHARMACOLOGY & THERAPEUTICS, 1991, 52 (02) :211-225
[5]   PHOSPHOROTHIOATE ANALOGS OF NUCLEOTIDES [J].
ECKSTEIN, F .
ACCOUNTS OF CHEMICAL RESEARCH, 1979, 12 (06) :204-210
[6]  
Giachetti Cristina, 1996, Journal of Investigative Dermatology, V107, P256, DOI 10.1111/1523-1747.ep12329755
[7]  
GREEN PG, 1993, PHARM SKIN PENETRATI, P311
[8]   GROWTH-INHIBITION OF HUMAN KERATINOCYTES BY ANTISENSE C-MYC OLIGOMER IS NOT COUPLED TO INDUCTION OF DIFFERENTIATION [J].
HASHIRO, M ;
MATSUMOTO, K ;
OKUMURA, H ;
HASHIMOTO, K ;
YOSHIKAWA, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 174 (01) :287-292
[9]   A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo [J].
Mata, JE ;
Joshi, SS ;
Palen, B ;
Pirruccello, SJ ;
Jackson, JD ;
Elias, N ;
Page, TJ ;
Medlin, KL ;
Iversen, PL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 144 (01) :189-197
[10]   RUNAWAY TELOMERE ELONGATION CAUSED BY TELOMERASE RNA GENE-MUTATIONS [J].
MCEACHERN, MJ ;
BLACKBURN, EH .
NATURE, 1995, 376 (6539) :403-409